Yuka Ikenaga

732 total citations
11 papers, 601 citations indexed

About

Yuka Ikenaga is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, Yuka Ikenaga has authored 11 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Yuka Ikenaga's work include Pharmacogenetics and Drug Metabolism (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Treatment of Major Depression (3 papers). Yuka Ikenaga is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Treatment of Major Depression (3 papers). Yuka Ikenaga collaborates with scholars based in Japan, Belgium and Italy. Yuka Ikenaga's co-authors include Junichi Azuma, Tsuyoshi Fukuda, Gaku Okugawa, Masataka Wakeno, Masaki Kato, Toshihiko Kinoshita, Shuichi Fukuen, Yoshiteru Takekita, Kazuhiro Fukuda and Isamu Yamamoto and has published in prestigious journals such as Progress in Neuro-Psychopharmacology and Biological Psychiatry, European Journal of Clinical Pharmacology and International Clinical Psychopharmacology.

In The Last Decade

Yuka Ikenaga

11 papers receiving 577 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuka Ikenaga Japan	8	219	169	150	143	129	11	601
Beatrice Oneda Switzerland	12	251 1.1×	129 0.8×	89 0.6×	222 1.6×	163 1.3×	25	734
Daniel T. Barratt Australia	16	212 1.0×	116 0.7×	149 1.0×	296 2.1×	99 0.8×	34	952
Jun Miura Japan	10	186 0.8×	90 0.5×	69 0.5×	48 0.3×	49 0.4×	24	399
Ida Rudberg Norway	9	285 1.3×	87 0.5×	173 1.2×	102 0.7×	135 1.0×	11	631
J. Cobaleda Spain	14	376 1.7×	146 0.9×	84 0.6×	80 0.6×	100 0.8×	20	615
Jennifer A. Graf United States	10	159 0.7×	110 0.7×	75 0.5×	85 0.6×	106 0.8×	15	607
Shu Chih Liu Taiwan	10	130 0.6×	53 0.3×	101 0.7×	69 0.5×	87 0.7×	12	372
Evangelia Eirini Tsermpini Greece	12	193 0.9×	26 0.2×	80 0.5×	76 0.5×	104 0.8×	26	552
Hsiang‐Wei Kuo Taiwan	14	81 0.4×	60 0.4×	54 0.4×	78 0.5×	128 1.0×	29	500
Roza Ghotbi Sweden	6	220 1.0×	77 0.5×	142 0.9×	47 0.3×	121 0.9×	6	486

Countries citing papers authored by Yuka Ikenaga

Since Specialization

Citations

This map shows the geographic impact of Yuka Ikenaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuka Ikenaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuka Ikenaga more than expected).

Fields of papers citing papers by Yuka Ikenaga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuka Ikenaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuka Ikenaga. The network helps show where Yuka Ikenaga may publish in the future.

Co-authorship network of co-authors of Yuka Ikenaga

This figure shows the co-authorship network connecting the top 25 collaborators of Yuka Ikenaga. A scholar is included among the top collaborators of Yuka Ikenaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuka Ikenaga. Yuka Ikenaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Ikenaga, Yuka, et al.. (2023). Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist. European Journal of Clinical Pharmacology. 79(6). 801–813. 6 indexed citations

Yoshida, Kosuke, Hidenori Yasuhara, Yuka Ikenaga, et al.. (2021). Prediction of human pharmacokinetics for low‐clearance compounds using pharmacokinetic data from chimeric mice with humanized livers. Clinical and Translational Science. 15(1). 79–91. 5 indexed citations

Kuriyama, Chiaki, Keiko Nakayama, Yasuaki Matsushita, et al.. (2015). The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. Journal of Pharmacological Sciences. 127(4). 456–461. 23 indexed citations

Kato, Masaki, Tsuyoshi Fukuda, Alessandro Serretti, et al.. (2007). ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 32(2). 398–404. 140 indexed citations

Kato, Masaki, Tsuyoshi Fukuda, Masataka Wakeno, et al.. (2006). Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. Neuropsychobiology. 53(4). 186–195. 130 indexed citations

Kato, Masaki, Yuka Ikenaga, Masataka Wakeno, et al.. (2005). Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International Clinical Psychopharmacology. 20(3). 151–156. 66 indexed citations

Fukuda, Tsuyoshi, et al.. (2005). Novel Structure of the CYP2D6 Gene that Confuses Genotyping for the CYP2D6*5 Allele. Drug Metabolism and Pharmacokinetics. 20(5). 345–350. 14 indexed citations

Ikenaga, Yuka, et al.. (2005). The Frequency of Candidate Alleles for CYP2D6 Genotyping in the Japanese Population with an Additional Respect to the −1584C to G Substitution. Drug Metabolism and Pharmacokinetics. 20(2). 113–116. 18 indexed citations

Kato, Masaki, Masataka Wakeno, Gaku Okugawa, et al.. (2004). Clinical comparison of paroxetine and fluvoxamine considering of the serotonin transporter promoter polymorphism in patients with affective disorder. International Clinical Psychopharmacology. 19(3). 175–175. 3 indexed citations

10.

Fukuda, Tsuyoshi, Shinya Onishi, Shuichi Fukuen, et al.. (2003). CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. The Pharmacogenomics Journal. 4(1). 34–39. 41 indexed citations

11.

Fukuen, Shuichi, Tsuyoshi Fukuda, Yuka Ikenaga, et al.. (2002). Novel detection assay by PCR???RFLP and frequency of the CYP3A5 SNPs, CYP3A5 *3 and *6, in a Japanese population. Pharmacogenetics. 12(4). 331–334. 155 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact